A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.

PTEN and the pan phosphoinositide 3-kinase (PI3K) inhibitor 2-(4-morpholinyl)-8-phenyl-4H-1 benzopyran-4-one (LY294002) exert significant control over tumor-induced angiogenesis and tumor growth in vivo. The LY294002 compound is not a viable drug candidate due to poor pharmacologic variables of insolubility and short half-life. Herein, we describe the development and antitumor activity of a novel RGDS-conjugated LY294002 prodrug, termed SF1126, which is designed to exhibit increased solubility and bind to specific integrins within the tumor compartment, resulting in enhanced delivery of the active compound to the tumor vasculature and tumor. SF1126 is water soluble, has favorable pharmacokinetics, and is well tolerated in murine systems. The capacity of SF1126 to inhibit U87MG and PC3 tumor growth was enhanced by the RGDS integrin (alpha v beta 3/alpha 5 beta 1) binding component, exhibiting increased activity compared with a false RADS-targeted prodrug, SF1326. Antitumor activity of SF1126 was associated with the pharmacokinetic accumulation of SF1126 in tumor tissue and the pharmacodynamic knockdown of phosphorylated AKT in vivo. Furthermore, SF1126 seems to exhibit both antitumor and antiangiogenic activity. The results support SF1126 as a viable pan PI3K inhibitor for phase I clinical trials in cancer and provide support for a new paradigm, the application of pan PI3K inhibitory prodrugs for the treatment of cancer.

[1]  D. Durden,et al.  Mechanisms of Disease: the PI3K–Akt–PTEN signaling node—an intercept point for the control of angiogenesis in brain tumors , 2007, Nature Clinical Practice Neurology.

[2]  G. Evan.  Can't kick that oncogene habit. , 2006, Cancer cell.

[3]  M. Waterfield,et al.  Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors. , 2006, Bioorganic & medicinal chemistry.

[4]  S. Lowe,et al.  Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. , 2006, Cancer research.

[5]  V. Rangnekar,et al.  The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target. , 2006, Cancer research.

[6]  M. Waterfield,et al.  Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors. , 2006, Bioorganic & medicinal chemistry.

[7]  J. Nakamura,et al.  Inhibition of phosphatidylinositol-3-kinase causes increased sensitivity to radiation through a PKB-dependent mechanism. , 2005, International journal of radiation oncology, biology, physics.

[8]  T. Tsuruo,et al.  Binding and phosphorylation of par-4 by akt is essential for cancer cell survival. , 2005, Molecular cell.

[9]  Emilio Hirsch,et al.  Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis , 2005, Nature Medicine.

[10]  P. De,et al.  CSK negatively regulates nerve growth factor induced neural differentiation and augments AKT kinase activity. , 2005, Experimental cell research.

[11]  Yiling Lu,et al.  Use of Reverse Phase Protein Microarrays and Reference Standard Development for Molecular Network Analysis of Metastatic Ovarian Carcinoma* , 2005, Molecular & Cellular Proteomics.

[12]  J. Nakamura,et al.  Inhibition of phosphatidylinositol-3-kinase causes cell death through a protein kinase B (PKB)-dependent mechanism and growth arrest through a PKB-independent mechanism. , 2005, International journal of radiation oncology, biology, physics.

[13]  Zhaobin Zhang,et al.  Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. , 2005, Cancer research.

[14]  K. Berns,et al.  Akt and 14-3-3η regulate Miz1 to control cell-cycle arrest after DNA damage , 2005, Nature Cell Biology.

[15]  J. Nakamura,et al.  PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas , 2005, Journal of Neuro-Oncology.

[16]  M. Kanzaki,et al.  Phosphatidylinositol 4,5-Bisphosphate Regulates Adipocyte Actin Dynamics and GLUT4 Vesicle Recycling* , 2004, Journal of Biological Chemistry.

[17]  E. Bernhard,et al.  Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin , 2004, Oncogene.

[18]  J. Grandis,et al.  Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. , 2004, Cancer treatment reviews.

[19]  D. Durden,et al.  PTEN and phosphatidylinositol 3'-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment. , 2003, Cancer research.

[20]  L. Mayo,et al.  The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. , 2002, Trends in biochemical sciences.

[21]  K. Inoki,et al.  TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling , 2002, Nature Cell Biology.

[22]  Takashi Tsuruo,et al.  Akt-dependent Phosphorylation of p27Kip1Promotes Binding to 14-3-3 and Cytoplasmic Localization* , 2002, The Journal of Biological Chemistry.

[23]  C. Kontos,et al.  PTEN Modulates Vascular Endothelial Growth Factor-Mediated Signaling and Angiogenic Effects* , 2002, The Journal of Biological Chemistry.

[24]  G. Mills,et al.  Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. , 2002, Cancer research.

[25]  J. Dixon,et al.  PTEN Protects p53 from Mdm2 and Sensitizes Cancer Cells to Chemotherapy* , 2002, The Journal of Biological Chemistry.

[26]  A. Harris,et al.  Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway. , 2001, Cancer research.

[27]  G. Mills,et al.  Linking molecular therapeutics to molecular diagnostics: Inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[28]  L. Mayo,et al.  A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Michael P. Myers,et al.  PTEN controls tumor-induced angiogenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  John F. Timms,et al.  Cellular function of phosphoinositide 3-kinases: Implications for development, immunity, homeostasis, and cancer , 2001 .

[31]  K. Okkenhaug,et al.  Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. , 2001, Annual review of cell and developmental biology.

[32]  R. Medema,et al.  AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1 , 2000, Nature.

[33]  G. Semenza,et al.  Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. , 2000, Cancer research.

[34]  G. Mills,et al.  In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  L. Pfeffer,et al.  NF-κB activation by tumour necrosis factor requires the Akt serine–threonine kinase , 1999, Nature.

[36]  H. Fu,et al.  Suppression of apoptosis signal-regulating kinase 1-induced cell death by 14-3-3 proteins. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[37]  L. Cantley,et al.  New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[38]  A. King,et al.  The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338 , 1998, Nature.

[39]  K Y Hui,et al.  A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). , 1994, The Journal of biological chemistry.

[40]  P. Humphrey,et al.  Structural alterations of the epidermal growth factor receptor gene in human gliomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.